期刊
MOLECULAR PHARMACEUTICS
卷 15, 期 5, 页码 1791-1799出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b01103
关键词
iron oxide nanoparticles; adjuvant; vaccine; cancer; vaccine delivery
资金
- Projects of National Science Foundation of China [81570992]
- SUMHS seed foundation project [HMSF-16-21-010]
- Science and Technology Development Foundation of Pudong New District, Shanghai, China [PKJ2016-Y55, PWZxq2017-03]
- Interdisciplinary Program of Shanghai Jiao Tong University [YG2017MS22, YG2015MS06, YG2015QN12, YG2017QN56, YG2016QN22]
Modem therapeutic cancer vaccines need simple and effective formulations to enhance both humoral and cellular immune responses. Nanoparticles have obtained more and more attention in the development of vaccine delivery platforms. Moreover, nanoparticles-based vaccine delivery platform has high potential for improving the immunogenicity of vaccine. The Food and Drug Administration (FDA) has approved many types of iron oxide nanoparticles for clinical use, such as treating iron deficiency, contrast agents for magnetic resonance imaging (MRI) and drug delivery platforms. In this study, we explored a novel combined use of iron oxide nanoparticles (superparamagnetic Fe3O4 nanoparticles) as a vaccine delivery platform and immune potentiator, and investigated how this formulation affected cytokine expression in macrophages and dendritic cells (DCs) in vitro and tumor growth in vivo. Comparing with soluble OVA alone and iron oxide nanoparticles alone, we found significant differences in immune responses and tumor inhibition induced by OVA formulated with iron oxide nanoparticles. Our iron oxide nanoparticles greatly promoted the activation of immune cells and cytokine production, inducing potent humoral and cellular immune responses. These results suggest that this nanoparticle-based delivery system has strong potential to be utilized as a general platform for cancer vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据